Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sandoz Debuts US Combigan Rival

Follows Apotex Launch Of Authorized Generic Earlier This Year

Executive Summary

Sandoz has expanded its ophthalmic portfolio with the introduction of the first US generic rival to Combigan. However, the firm will have to contend with an authorized generic launched earlier this year by Apotex.

You may also be interested in...



Generics Bulletin Editor’s Picks For Q2 2022

Looking back over the second quarter of 2022, Generics Bulletin executive editor Dave Wallace picks out highlights from April to June that include multiple first generic and biosimilar launches, some noteworthy executive moves, further preparation for biosimilar competition to Humira in the US, and a major European industry conference.

Sandoz Stays Shut Out On Combigan In US Until 2022

A US district court was right to bar Sandoz launching a generic version of Allergan’s Combigan glaucoma treatment due to limiting safety and efficacy clauses in three patents, the US Court of Appeals has confirmed.

US Bill Seeks To Eliminate Biosimilar Interchangeability Trial Burden

Sen. Mike Lee, R-UT, has introduced draft legislation in the US that would stop the FDA from requiring biosimilars to conduct ‘unnecessary’ switching studies in order to obtain an interchangeability designation.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151806

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel